What Are the Long-Term Side Effects of Carvedilol?

Carvedilol is generally well tolerated over months and years, but like all beta-blockers, it carries a profile of long-term side effects that range from mild annoyances to rare but serious complications. The most commonly reported issues with extended use include fatigue, dizziness, weight gain, sexual dysfunction, and cold extremities. Less obvious but clinically relevant effects involve shifts in blood sugar handling, changes in cholesterol levels, and potential impacts on lung function. Understanding what to watch for and which effects are genuinely common versus exceedingly rare can help you have a more productive conversation with your doctor about whether the drug’s benefits still outweigh its costs.

Fatigue, Dizziness, and Slow Heart Rate

The side effects you are most likely to notice early on and that can persist with long-term use are fatigue and dizziness. These stem from the drug’s core mechanism: carvedilol blocks beta-adrenergic receptors, which slows the heart rate and lowers blood pressure. For most people, that is the therapeutic goal. But when the heart slows a bit more than intended, you feel it as tiredness, lightheadedness when standing up, or a general sense of low energy. These symptoms tend to be dose-dependent, meaning they are worse at higher doses and sometimes improve if the dose is reduced.

Bradycardia, a resting heart rate that drops below the normal range, is the more clinically significant version of this effect. A large observational study comparing carvedilol and metoprolol found that the incidence of emergent bradycardia was relatively low for both drugs, around 18 cases per 1,000 person-years. After adjusting for differences between the patient populations, metoprolol actually carried a higher risk of bradycardia than carvedilol did.¹ So while a slow heart rate is a real concern, carvedilol does not appear to be the worst offender among commonly prescribed beta-blockers.

Weight Gain

Weight gain is one of the more frustrating long-term side effects, and it is well documented. In the COPERNICUS trial, which studied patients with severe heart failure, those taking carvedilol gained an average of about 1.2 kg (roughly 2.6 pounds) over a year, while patients on placebo showed essentially no change. Carvedilol-treated patients were also about 37% more likely to experience a clinically significant weight gain of 5% or more.²

The flip side of this finding matters, though. In patients with severe heart failure, wasting (cachexia) is a serious problem, and carvedilol reduced the risk of dangerous weight loss by about a third. So what counts as a side effect in one context can be protective in another. For people taking carvedilol for hypertension who are not at risk of cachexia, the weight gain is more straightforwardly unwelcome. The mechanism likely involves reduced metabolic rate from beta-blockade plus possible fluid retention. If your weight is creeping up on carvedilol, it is worth discussing with your prescriber rather than just chalking it up to aging or diet.

Sexual Dysfunction

This is one of the side effects people are most reluctant to bring up, and also one of the most studied. In a crossover trial comparing carvedilol to valsartan (an angiotensin receptor blocker) in men with hypertension, sexual activity dropped significantly during carvedilol treatment. The average number of monthly sexual encounters fell from about 8 at baseline to roughly 4 after the first month on carvedilol, and continued declining to about 3.7 with ongoing use. Erectile dysfunction was reported by about 14% of men taking carvedilol, compared with less than 1% on valsartan.³

This is not unique to carvedilol; beta-blockers as a class have a reputation for impairing sexual function. The mechanism involves both reduced blood flow and changes in the nervous system signals that regulate arousal and erection. If you have noticed this problem, switching to a different class of blood pressure medication is sometimes an option, depending on why carvedilol was prescribed in the first place. The data suggest that this effect does not improve with continued use and may worsen over time, which makes it an important long-term consideration rather than something you should just wait out.

Blood Sugar and Metabolic Effects

Beta-blockers have long been associated with worsening blood sugar control, which is a particular concern for people with diabetes or prediabetes. Carvedilol has a somewhat more favorable metabolic profile than many of its relatives. The GEMINI trial, which compared carvedilol to metoprolol in patients with both hypertension and type 2 diabetes, found that carvedilol was associated with more stable blood sugar levels and improved insulin sensitivity relative to metoprolol.⁴ Animal research has reinforced this, showing that carvedilol can improve glucose tolerance and insulin sensitivity in models of diet-induced obesity.⁵

That said, “better than metoprolol” is not the same as “no effect.” Carvedilol still blunts some of the body’s normal adrenergic responses to low blood sugar, which means it can mask the warning signs of hypoglycemia. Normally, when your blood sugar drops too low, your body releases adrenaline, causing a fast heartbeat, shakiness, and sweating that alert you to eat something. Beta-blockers dampen that alarm system. If you have diabetes and use insulin or sulfonylureas, this masking effect is something to discuss with your care team, because it persists as long as you are on the drug.

Cholesterol and Lipid Changes

Traditional beta-blockers tend to nudge cholesterol numbers in the wrong direction, raising triglycerides and sometimes lowering HDL (the “good” cholesterol). Carvedilol appears to be somewhat gentler on lipids, likely because of its additional alpha-blocking and antioxidant properties. A study comparing carvedilol to metoprolol in diabetic patients with hypertension found that carvedilol led to a roughly 10% greater reduction in triglycerides and a small but significant reduction in total cholesterol compared with metoprolol.⁶

When compared to labetalol, another combined alpha-beta blocker, carvedilol held cholesterol levels essentially stable over a year, while labetalol users saw a small increase in total cholesterol. Triglycerides, however, rose modestly with both drugs.⁷ The practical takeaway is that carvedilol is unlikely to dramatically change your lipid panel, but it is not entirely lipid-neutral either. If you already have borderline cholesterol or triglyceride levels, monitoring them periodically while on long-term carvedilol is reasonable.

Breathing and Lung Function

Because carvedilol blocks beta-2 receptors in the lungs (not just the beta-1 receptors in the heart), it can potentially cause bronchospasm, or tightening of the airways. This matters most for people with asthma or chronic obstructive pulmonary disease (COPD). A study in heart failure patients who also had airway disease found a stark split: about 84% of patients with COPD tolerated carvedilol safely, but only 50% of patients with asthma did.⁸

For COPD patients in that study, peak expiratory flow actually increased by about 17% after a carvedilol dose, suggesting the drug was not meaningfully worsening airflow. Asthma patients, on the other hand, showed no improvement and had a much higher withdrawal rate due to wheezing. If you have COPD, long-term carvedilol use is generally feasible under close monitoring. If you have asthma, the drug is typically avoided or used with extreme caution. This is not a side effect that tends to develop over time; if you are going to have problems, they usually appear early. But ongoing vigilance is still warranted, especially if your lung disease progresses.

Cold Hands and Peripheral Circulation

Cold fingers and toes are a classic beta-blocker complaint, and carvedilol is no exception. Beta-blockade reduces the heart’s output and can constrict blood vessels in the extremities, leaving your hands and feet chilly. However, carvedilol’s alpha-blocking property gives it a partial advantage here. Compared to atenolol, a pure beta-blocker, carvedilol shifted blood vessel dynamics in the fingers toward vasodilation and better compliance, and it reduced the vasoconstrictor response to cooling.⁹

In practical terms, you may still notice cooler extremities on carvedilol, but the effect tends to be milder than with older beta-blockers. If you already have Raynaud’s phenomenon or significant peripheral vascular disease, this is something your doctor should weigh when choosing your medication. The effect is persistent for as long as you take the drug, though it does not typically worsen over time.

Liver Safety

Liver injury from carvedilol is rare, but it does exist in the medical literature and it is worth knowing about because it can be serious if missed. Case reports have documented carvedilol-induced hepatotoxicity presenting as elevated liver enzymes, itching, and jaundice. In very rare instances, a chronic cholestatic pattern has developed that could progress toward cirrhosis if the drug was not stopped in time.¹⁰

An important practical point: the reaction may recur if you are switched to a different beta-blocker, suggesting a possible cross-sensitivity within the drug class.¹¹ If you develop unexplained itching, dark urine, or yellowing of the skin while on carvedilol, your doctor will likely check liver function tests. The good news is that early withdrawal of the drug typically allows the liver to recover. This is not something that requires routine screening for most patients, but it is worth flagging if you already have liver disease or if new symptoms appear.

Kidney Function

Kidney concerns come up with many blood pressure medications, so it is reasonable to wonder whether carvedilol poses a risk to renal function over time. The evidence here is reassuring. A study of long-term carvedilol therapy in patients with essential hypertension found no significant changes in glomerular filtration rate, renal plasma flow, blood urea nitrogen, or serum creatinine. Renal vascular resistance actually decreased, consistent with the drug’s vasodilatory properties.¹² While individual circumstances vary, particularly if kidney disease is already present, carvedilol does not appear to be a drug that independently harms the kidneys with prolonged use.

Stopping Carvedilol Abruptly

This is not a side effect of taking carvedilol, but of stopping it, and it is arguably the most dangerous long-term consideration. Beta-blockers as a class can cause a withdrawal syndrome if discontinued abruptly. Symptoms typically appear about 36 to 72 hours after the last dose and can include nervousness, rapid heartbeat, headache, agitation, and nausea. In more severe cases, blood pressure can rebound to pre-treatment levels or higher, and myocardial ischemia (insufficient blood flow to the heart) can occur.¹³

The exact incidence of this syndrome appears to be rare at standard doses, but the consequences can be severe enough that the universal guidance is to taper gradually rather than stop all at once. If you are considering discontinuing carvedilol for any reason, whether because of side effects or a change in your treatment plan, always do so under medical supervision with a step-down schedule.

Overall Tolerability With Long-Term Use

Despite this catalog of potential issues, carvedilol has a reasonably good track record for long-term adherence. In the U.S. Carvedilol Heart Failure Study, dropout rates during the double-blind treatment phase were about 11% in both the carvedilol and placebo groups, meaning carvedilol did not drive people off the medication any more than a sugar pill did.¹⁴ That is a striking finding in patients with severe heart failure, a population that tends to be sensitive to medication side effects.

Part of what makes carvedilol more tolerable than older beta-blockers is its dual mechanism. By blocking alpha-1 receptors in addition to beta receptors, it causes blood vessel dilation that partially offsets some of the classic beta-blocker complaints like cold extremities and worsened blood sugar. Its antioxidant properties may contribute to the relatively benign lipid profile. None of this makes the side effects disappear, but it shifts the balance enough that many people can stay on the drug for years. The most important thing you can do is stay aware of the potential effects, report new symptoms to your doctor, and never adjust or stop the medication on your own.

How Carvedilol Compares to Other Beta-Blockers on Side Effects

A recurring theme across the research is that carvedilol tends to cause fewer metabolic side effects than selective beta-blockers like metoprolol or atenolol, while being somewhat less friendly to the lungs and sexual function. The GEMINI trial showed better insulin sensitivity with carvedilol than metoprolol.⁴ The lipid data similarly favor carvedilol over metoprolol for triglyceride levels.⁶ And the bradycardia data suggest a lower adjusted risk with carvedilol than metoprolol.¹

On the other hand, carvedilol’s non-selective beta-blockade means it hits the lungs harder, which is why the tolerability data for asthma patients are worse than what you would expect from a beta-1 selective agent. And while sexual dysfunction is common across the class, the crossover study comparing carvedilol to valsartan showed a particularly steep decline in sexual activity. No beta-blocker is perfect, and the choice between them often comes down to which trade-offs matter most for a given patient’s medical profile and quality of life.

1
The American Journal of Medicine. Risk of Emergent Bradycardia Associated with the Use of Carvedilol and Metoprolol in Routine Clinical Practice
2
PubMed Central. Effect of beta‐adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial
3
PubMed. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study
4
American College of Cardiology. Glycemic Effects in Diabetes Mellitus: Carvedilol – Metoprolol Comparison in Hypertensives Trial – GEMINI
5
PubMed Central. Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice
6
PubMed. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients
7
American Journal of Hypertension. Results of Therapy With Carvedilol, a β-Blocker Vasodilator With Antioxidant Properties, in Hypertensive Patients
8
PubMed. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma
9
PubMed. Effects of carvedilol and atenolol on arterial pulse curves (plethysmography) and finger temperature after hand cooling
10
PubMed Central. Carvedilol-Induced Liver Injury, a Rare Cause of Mixed Hepatitis: A Clinical Case
11
PubMed. Hepatotoxicity associated with carvedilol
12
PubMed. Effect of long-term carvedilol therapy on renal function in essential hypertension
13
PubMed. Withdrawal syndrome following cessation of antihypertensive drug therapy
14
PubMed. Safety and efficacy of carvedilol in severe heart failure